Article
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.
The Journal of antimicrobial chemotherapy - 1 Feb 2024
Abdullahi Adam, Diaz Ana Garcia, Fopoussi Olga Mafotsing, Beloukas Apostolos, Fokom Defo Victoire, Kouanfack Charles, Torimiro Judith, Geretti Anna Maria
Abstract excerpt
BACKGROUND: Maintenance monotherapy with ritonavir-boosted darunavir has yielded variable outcomes and is not recommended. Trial samples offer valuable opportunities for detailed studies. We analysed samples from a 48 week trial in Cameroon to obtain a detailed characterization of drug resistance. METHODS: Following failure of NNRTI-based therapy and virological suppression on PI-based therapy, participants were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.